Insider · CIK 0001756438
Danny L. Dearen
Files at NSPR (InspireMD, Inc.), BBNX (Beta Bionics, Inc.). First filing -, latest -.
In brief
Danny L. Dearen files SEC Form 4 as director at NSPR (InspireMD, Inc.), and also at BBNX (Beta Bionics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Danny L. Dearen has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | BBNX Beta Bionics, Inc. | AGrant or award Common Stock | +16,965 | $0.00 | $0 | 32,209 | May 26, 2026 |
| Jan 14, 2026 | NSPR InspireMD, Inc. | AGrant or award Common Stock | +44,030 | $0.00 | $0 | 102,047 | Jan 16, 2026 |
| Jan 13, 2026 | BBNX Beta Bionics, Inc. | AGrant or award Common Stock | +3,997 | $0.00 | $0 | 15,244 | Jan 14, 2026 |
| Mar 15, 2025 | BBNX Beta Bionics, Inc. | AGrant or award Common Stock | +11,247 | $0.00 | $0 | 11,247 | Mar 18, 2025 |
Questions about Danny L. Dearen
Answered from the filings on this page, as of the latest one.
Is Danny L. Dearen buying or selling?
Danny L. Dearen has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Danny L. Dearen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Danny L. Dearen has 0.
Where does Danny L. Dearen file Form 4?
Danny L. Dearen has filed Form 4 at NSPR (InspireMD, Inc.); BBNX (Beta Bionics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.